Top

International Urogynecology Journal

Published in:

01-08-2014 | Original Article

Do predictive parameters exist for therapy with duloxetine in women with stress urinary incontinence?

Authors: Nadine Schwertner-Tiepelmann, Frank Schwab, Ralf Tunn

Published in: International Urogynecology Journal | Issue 8/2014

Abstract

Introduction and hypothesis

To determine whether predictive parameters exist for successful duloxetine therapy in women with stress urinary incontinence (SUI).

Methods

Secondary analysis was performed of 1,714 women who received duloxetine in the Stress Urinary Incontinence Treatment (SUIT) study, a 12-month longitudinal observational study to evaluate the results and direct costs of SUI treatment. Data of 1,087 women were analyzed. Univariate and multivariate analyses (stepwise forward logistic regression) were performed to investigate factors for discontinuation of treatment.

Results

Parameters that significantly reduced the probability of treatment termination were smoking and a body mass index (BMI) <20, while obesity (BMI >30) increased the probability in the univariate analysis. In the multivariate analysis significantly reduced likelihoods of duloxetine treatment discontinuation were found for an age >65 years, country, and 7 to 13 incontinence episodes per week. Co-medication, particularly anti-cholinergics, was significantly associated with therapy termination. Previous SUI surgery had no effect.

Conclusions

Identification of predictive parameters for successful therapy with duloxetine in women with SUI is desirable, and co-medications should be critically considered.

Lin AT, Sun MJ, Tai HL et al (2008) Duloxetine versus placebo for the treatment of women with stress predominant urinary incontinence in Taiwan: a double-blind, randomized, placebo-controlled trial. BMC Urol 8:2PubMedCentralPubMedCrossRef

Millard RJ, Moore K, Rencken R, Yalcin I, Bump RC (2004) Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. BJU Int 93:311–318PubMedCrossRef

Viktrup L, Yalcin I (2007) Duloxetine treatment of stress urinary incontinence in women: effects of demographics, obesity, chronic lung disease, hypoestrogenism, diabetes mellitus, and depression on efficacy. Eur J Obstet Gynecol Reprod Biol 133:105–113PubMedCrossRef

Ghoniem GM, Van Leeuwen JS, Elser DM et al (2005) A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. J Urol 173:1647–1653PubMedCrossRef

Dmochowski RR, Miklos JR, Norton PA, Zinner NR, Yalcin I, Bump RC (2003) Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol 170:1259–1263PubMedCrossRef

van Kerrebroeck P, Abrams P, Lange R, Slack W, Wyandaele J, Yalcin I, Bump RC (2004) Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. BJOG 111:249–257PubMedCrossRef

Manning M, Gotsch U, Minarzyk A, Quail D, Gross A, Pages I, Methfessel HD, Michel MC (2009) How are women with SUI-symptoms treated with duloxetine in real life practice?—preliminary results from a large observational study in Germany. Int J Clin Pract 63:1724–1733PubMedCrossRef

Bump RC, Voss S, Beardsworth A, Manning M, Zhao YD, Chen W (2008) Long-term efficacy of duloxetine in women with stress urinary incontinence. BJU Int 102:214–218PubMedCrossRef

Weinstein DL, Cohen JS, Liu C, Meadows ES, Plouffe L Jr, Muram D, DESIRE Study Group (2006) Duloxetine in the treatment of women with stress urinary incontinence: results from DESIRE (Duloxetine Efficacy and Safety for Incontinence in Racial and Ethnic populations). Curr Med Res Opin 22:2121–2129PubMedCrossRef

10.

Freeman RM (2006) Initial management of stress urinary incontinence: pelvic floor muscle training and duloxetine. BJOG 113 [Suppl 1]:10–16PubMedCrossRef

11.

Duckett JR, Vella M, Kavalakuntla G, Basu M (2007) Tolerability and efficacy of duloxetine in a nontrial situation. BJOG 114:543–547PubMedCrossRef

12.

Castro-Diaz D, Palma PC, Bouchard C et al (2007) Effect of dose escalation on the tolerability and efficacy of duloxetine in the treatment of women with stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 18:919–929PubMedCrossRef

13.

Hurley DJ, Turner CL, Yalcin I, Viktrup L, Baygani SK (2006) Duloxetine for the treatment of stress urinary incontinence in women: an integrated analysis of safety. Eur J Obstet Gynecol Reprod Biol 125:120–128PubMedCrossRef

14.

Drutz H (2006) Duloxetine in women awaiting surgery. BJOG 113:17–21PubMedCrossRef

15.

Bent AE, Gousse AE, Hendrix SL, Klutke CG, Monga AK, Yuen CK, Muram D, Yalcin I, Bump RC (2008) Duloxetine compared with placebo for the treatment of women with mixed urinary incontinence. Neurourol Urodyn 27:212–221PubMedCrossRef

16.

van de Vaart H, Falconer C, Quail D, Timlin L, Manning M, Tincello D, Tunn R (2010) Patient reported outcomes tools in an observational study of female stress urinary incontinence. Neurourol Urodyn 29:348–353PubMed

17.

Flockhart D (2007) Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine. http://medicine.iupui.edu/clinpharm/ddis/table.aspx. Accessed 25 February 2013

18.

Skinner MH, Kuan HY, Pan A, Sathirakul K, Knadler MP, Gonzales CR, Yeo KP, Reddy S, Lim M, Ayan-Oshodi M, Wise SD (2003) Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther 73:170–177PubMedCrossRef

19.

Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome p450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics 5:6–13CrossRef

20.

Brosen K (1990) Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics. Clin Pharmacokinet 18:220–239PubMedCrossRef

21.

Sindrup SH, Brosen K, Gram LF et al (1992) The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 51:278–287PubMedCrossRef

22.

Gjerde JHM, Breilid H, Lundgren S, Varhaug JE, Kisanga ER, Mellgren G, Steen VM (2008) Lien EA Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol 19:56–61PubMedCrossRef

23.

KBV (2009) Duloxetin (Cymbalta®). Wirkstoff AKTUELL. Vol. 03: KBV

24.

Sternbach H (1991) The serotonin syndrome. Am J Psychiatry 148:705–713PubMed

25.

Cardozo L, Lange R, Voss S, Bearthworth A, Manning L, Viktrup L, Zaoh YD (2010) Short- and long-term efficacy and safety of duloxetine in women with predominant stress urinary incontinence. Curr Med Res Opin 26:253–261PubMedCrossRef

26.

Ghotbi R, Christensen M, Roh HK, Ingelman-Sundberg M, Aklillu M, Bertillson L (2007) Comparisons of CYP 1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol 63:537–546PubMedCrossRef

27.

Thor KB (2003) Serotonin and norepinephrine involvement in efferent pathways to the urethral rhabdosphincter: implications for treating stress urinary incontinence. Urology 62:3–9PubMedCrossRef

28.

KBV (2008) Darifenacin. Wirkstoff AKTUELL. Vol. 02/2008

Title: Do predictive parameters exist for therapy with duloxetine in women with stress urinary incontinence?
Authors: Nadine Schwertner-Tiepelmann
Frank Schwab
Ralf Tunn
Publication date: 01-08-2014
Publisher: Springer London
Published in: International Urogynecology Journal / Issue 8/2014
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-014-2358-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Do predictive parameters exist for therapy with duloxetine in women with stress urinary incontinence?

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2014

Posture and micturition: does it really matter how a woman sits on the toilet?

Iatrogenic lower urinary tract injury at the time of pelvic reconstructive surgery: does previous pelvic surgery increase the risk?

Timing cervicovesical fistula repair with repeat cesarean section

Grading of evidence for bladder pain syndrome: a comparative review of study quality assessment methods

Lower urinary tract injuries during hysterectomy in women with a history of two or more cesarean deliveries: a secondary analysis

Short-term outcomes of Altis® single-incision sling procedure for stress urinary incontinence: a prospective single-center study